A Phase I, Single Ascending and Multiple Ascending Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LIFE-001
Latest Information Update: 13 Jul 2026
At a glance
- Drugs LIFE 001 (Primary)
- Indications Immunological disorders; Transplant rejection
- Focus Adverse reactions
- Sponsors LifeMine Therapeutics
Most Recent Events
- 07 Jul 2026 The protocol has been amended to change in time frame for primary endpoint.
- 07 Jul 2026 Planned number of patients changed from 150 to 160.
- 19 Mar 2026 Planned number of patients changed from 120 to 150.